• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EXAS

    Exact Sciences Corporation

    Subscribe to $EXAS
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

    IPO Year: 2001

    Exchange: NASDAQ

    Website: exactsciences.com

    Recent Analyst Ratings for Exact Sciences Corporation

    DatePrice TargetRatingAnalyst
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    1/2/2024$91.00Hold → Buy
    The Benchmark Company
    12/14/2023$90.00Buy
    Guggenheim
    12/13/2023$95.00Outperform
    Wolfe Research
    10/10/2023$90.00Neutral → Overweight
    Piper Sandler
    See more ratings

    Exact Sciences Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exact Sciences to Participate in May Investor Conference

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the suc

      5/2/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces First-Quarter 2025 Results

      First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

      5/1/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

      Robust research and data from multiple abstracts predict the Cologuard® test as the top choice for screening average-risk adults 45 and older, and confirms adoption across diverse demographics Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard® test along with abstracts on additional screening programs under development. The abstracts focused on the Cologuard test include data from more than half a million p

      4/29/25 6:59:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

      The new, highly sensitive, tumor-informed test detects up to 200 ctDNA* variants, identifying signs of colorectal cancer (CRC) recurrence up to two years earlier than imaging—making it one of the most comprehensive MRD tests available1,2 The Oncodetect test is available for order across multiple solid tumors† Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment pro

      4/22/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

      Comprehensive review confirms that the Oncotype DX Breast Recurrence Score® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, "Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights," affirms that the Oncotype DX test provides accurate and reliable information to help guide breast cancer treatment d

      4/14/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Schedules First Quarter 2025 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursday, May 1, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789-2701 Access cod

      4/1/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

      The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Cologuard Plus™, the most accurate noninvasive colorectal cancer screening (CRC) test reported in studies to date.* FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.1† This performance means fewer unnecessary follow-up colonoscopies—up to a 40% reduc

      3/31/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world. Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee engagement into the bedrock of how they do their work, motivate their teams, and achieve business outcomes. "Exact Sciences' success starts with our people, and winning the Gallup Exceptional Workplace Award for the second consecuti

      3/12/25 9:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences to Participate in March Investor Conferences

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. TD Cowen Health Care Conference, Boston Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET Raymond James Institutional Investors Conference, Orlando Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health

      2/24/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care

    Exact Sciences Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel & Sec Herriott James was granted 363 shares, increasing direct ownership by 2% to 15,585 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      5/8/25 4:30:09 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Director Trigg Leslie was granted 8,527 shares, increasing direct ownership by 877% to 9,499 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      5/1/25 4:31:25 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • New insider Trigg Leslie claimed ownership of 972 shares (SEC Form 3)

      3 - EXACT SCIENCES CORP (0001124140) (Issuer)

      5/1/25 4:30:04 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Conroy Kevin T decreased direct ownership by 9% to 779,944 units (SEC Form 5)

      5 - EXACT SCIENCES CORP (0001124140) (Issuer)

      4/29/25 4:10:17 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Conroy Kevin T gifted 163,000 shares, decreasing direct ownership by 21% to 602,120 units (SEC Form 5)

      5 - EXACT SCIENCES CORP (0001124140) (Issuer)

      4/29/25 4:09:17 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Amendment: Conroy Kevin T gifted 93,849 shares and received a gift of 43,126 shares, increasing direct ownership by 2% to 893,818 units (SEC Form 5)

      5/A - EXACT SCIENCES CORP (0001124140) (Issuer)

      4/29/25 4:08:31 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • EVP, Chief Financial Officer Bloomer Aaron converted options into 24,460 shares and covered exercise/tax liability with 10,837 shares (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      4/17/25 4:30:10 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • President and CEO Conroy Kevin T exercised 66,723 shares at a strike of $22.38 and covered exercise/tax liability with 48,929 shares, increasing direct ownership by 2% to 1,154,340 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      3/10/25 5:00:07 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SVP, General Counsel & Sec Herriott James converted options into 4,265 shares and covered exercise/tax liability with 2,006 shares, increasing direct ownership by 17% to 15,222 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      3/4/25 4:48:38 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • President and CEO Conroy Kevin T converted options into 40,310 shares and covered exercise/tax liability with 18,947 shares, increasing direct ownership by 2% to 1,136,546 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      3/4/25 4:47:42 PM ET
      $EXAS
      Medical Specialities
      Health Care

    Exact Sciences Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      11/13/24 2:58:53 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      11/8/24 10:52:39 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      10/7/24 11:37:08 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      6/7/24 12:07:25 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      2/13/24 5:04:35 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      2/9/24 8:40:49 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      1/23/24 9:40:30 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      10/10/23 1:51:48 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      2/10/23 12:31:38 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      2/9/23 11:19:19 AM ET
      $EXAS
      Medical Specialities
      Health Care

    Exact Sciences Corporation SEC Filings

    See more
    • SEC Form 10-Q filed by Exact Sciences Corporation

      10-Q - EXACT SCIENCES CORP (0001124140) (Filer)

      5/1/25 5:08:20 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      5/1/25 4:06:17 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Exact Sciences Corporation

      DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

      4/29/25 4:17:02 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by Exact Sciences Corporation

      DEF 14A - EXACT SCIENCES CORP (0001124140) (Filer)

      4/29/25 4:14:43 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Corporation filed SEC Form 8-K: Leadership Update

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      4/29/25 4:01:57 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form 10-K filed by Exact Sciences Corporation

      10-K - EXACT SCIENCES CORP (0001124140) (Filer)

      2/19/25 5:11:06 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Exact Sciences Corporation

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      2/19/25 4:08:58 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation

      SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      2/10/25 10:25:37 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      1/13/25 9:11:33 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Corporation filed SEC Form 8-K: Leadership Update

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      1/6/25 4:00:45 PM ET
      $EXAS
      Medical Specialities
      Health Care

    Exact Sciences Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Exact Sciences with a new price target

      Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

      4/10/25 12:41:36 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

      RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00

      3/13/25 7:36:02 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Exact Sciences with a new price target

      Barclays initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $70.00

      1/23/25 7:42:29 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Wells Fargo initiated coverage on Exact Sciences with a new price target

      Wells Fargo initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $75.00

      8/28/24 7:42:51 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Exact Sciences with a new price target

      Scotiabank initiated coverage of Exact Sciences with a rating of Sector Outperform and set a new price target of $70.00

      6/27/24 7:44:17 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Jefferies resumed coverage on Exact Sciences with a new price target

      Jefferies resumed coverage of Exact Sciences with a rating of Buy and set a new price target of $75.00

      6/3/24 8:49:48 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Exact Sciences from Hold to Buy and set a new price target of $91.00

      1/2/24 7:30:25 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Guggenheim initiated coverage on Exact Sciences with a new price target

      Guggenheim initiated coverage of Exact Sciences with a rating of Buy and set a new price target of $90.00

      12/14/23 6:58:16 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on Exact Sciences with a new price target

      Wolfe Research initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $95.00

      12/13/23 6:57:01 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Exact Sciences from Neutral to Overweight and set a new price target of $90.00

      10/10/23 7:28:29 AM ET
      $EXAS
      Medical Specialities
      Health Care

    Exact Sciences Corporation Financials

    Live finance-specific insights

    See more
    • Exact Sciences Announces First-Quarter 2025 Results

      First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

      5/1/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Schedules First Quarter 2025 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursday, May 1, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789-2701 Access cod

      4/1/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces Fourth Quarter 2024 Results

      Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus™, next-generation colorectal cancer screening test, Oncodetect™, molecular residual disease test, and Cancerguard™, multi-cancer screening test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic

      2/19/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date:    Wednesday, February 19, 2025 Time:    5 p.m. ET Webcast:    The live webcast can be accessed at www.exactsciences.com Telephone:    Domestic callers

      2/3/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces Third-Quarter 2024 Results

      Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights Total third quarter revenue of $709 million, an increase of 13% on a reported and core revenue basis, including Screening revenue of $545 million and Precision Oncology revenue of $164 million Net loss was $38 million, adjusted EBITDA was $99 million, and adjusted EBITDA margin increased 500 basis points to 14% Operating cash flow was $139 million with free cash flow of $113 million Received FDA approval for the Cologuard Plus™ test, the Company's next-generation Cologuard® test Presented data showing potential of its blood-based colorectal cancer screening test, with sens

      11/5/24 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Schedules Third Quarter 2024 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2024 webcast & conference call details           Date:   Tuesday, November 5, 2024    Time:   5 p.m. ET    Webcast:   The live webcast can be accessed at www.exactsciences.com    Telephone:   Domestic callers, dial 888-330-2384      Inte

      10/8/24 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces Second-Quarter 2024 Results

      Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second quarter highlights Delivered total second quarter revenue of $699 million, an increase of 12%, or 13% on a core revenue basis, including Screening revenue of $532 million and Precision Oncology revenue of $168 million Screened more than 1 million people with Cologuard for the first time during a quarter and tested a record number of cancer patients with Oncotype DX® Advanced pipeline by generating evidence supporting molecular residual disease, multi-cancer screening, and blood-based colorectal cancer screening tests Maintains full-year 2024 revenue guidance and

      7/31/24 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences schedules second quarter 2024 earnings call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2024 webcast & conference call details Date: Wednesday, July 31, 2024 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789

      7/8/24 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces First-Quarter 2024 Results

      First quarter highlights Delivered total first quarter revenue of $638 million, an increase of 6% on a reported and core revenue basis, including Screening revenue of $475 million and Precision Oncology revenue of $163 million Published Cologuard Plus™ test results from pivotal BLUE-C study in The New England Journal of Medicine Maintains full-year 2024 revenue and adjusted EBITDA guidance Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023. "The Exact Sciences team is of

      5/8/24 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Schedules First Quarter 2024 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2024 webcast & conference call details Date:   Wednesday, May 8, 2024 Time:   5 p.m. ET Webcast:   The live webcast can be accessed at www.exactsciences.com Telephone:   Domestic callers, dial 888-330-2384

      4/8/24 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care

    Exact Sciences Corporation Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

      Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl

      7/25/24 8:00:00 AM ET
      $EXAS
      $PODD
      Medical Specialities
      Health Care
      Medical/Dental Instruments
    • Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

      Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024. Mr. Bloomer brings to Exact Sciences more than 15 years of finance and accounting experience. He previously held leadership positions at Baxter International and 3M, where he helped improve financial results, drove operational rigor, led strategic growth initiatives, played key roles in portfolio management, acquisitions, and divestitures, and set corporate strategy and vision. At Baxter, Mr. Bloomer led corporate financial planning, reporting, and analytics (FP&A) as vice president. Prior to t

      4/15/24 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer

      In collaboration with The Blue Hat Foundation, "Box Out Colon Cancer" offers a timely spotlight on screening and prevention for the nation's #2 cancer-related killer1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with iconic pro basketball all-star and Kentucky legend Jamal Mashburn to introduce "Box Out Colon Cancer," in observance of Colorectal Cancer Awareness Month and the most exciting time in college basketball. This national educational campaign will encourage everyone 45 and older to screen for colon cancer – a disease affecting people of all races, genders, and ethnicities – in line with American Cancer Society reco

      3/7/24 7:59:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

      Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next-generation Cologuard® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: Expects total fourth quarter revenue of $645.5-$647.5 million, an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0-$487.0 million and Precision Oncology revenue of $159.5-$160.5 millionExpects total full-year 2023 revenue of $2.50 billion and 2024 revenue of $2.83 billionSubmitted final module of next-generation Cologuard premarket approval application to FDAAnnounces Jeff Elliott plans to step down as Executive Vice President and Chief Financia

      1/7/24 4:30:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CellMax Life Announces Expansion of Company Board With Leading Industry Experts

      Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

      4/6/23 9:00:00 AM ET
      $EXAS
      $HOLX
      Medical Specialities
      Health Care
      Medical Electronics
    • Diversey Appoints Katherine S. Zanotti to its Board of Directors

      FORT MILL, S.C., March 01, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Katherine S. Zanotti to the company's board of directors, effective March 1, 2022. This appointment will bring the total number of directors to eleven. "We are delighted to welcome Katherine (‘Kay') to our board. Kay's long history of leadership coupled with her extensive experience in sales and marketing within the foodservice and health care sectors makes her a great addition and helps position Diversey for continued growth and success," said Phil Wieland, CEO of Diversey.     Katherine S. Zanotti served as

      3/1/22 8:30:00 AM ET
      $CUTR
      $DSEY
      $EXAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Scipher Medicine® Appoints Sam Asgarian, M.D., MBA Chief Medical Officer

      Scipher Medicine, a precision immunology company matching patients with their most effective medication therapies, today announced the appointment of Sam Asgarian, M.D., MBA, as chief medical officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116006301/en/Sam Asgarian, M.D., MBA, Scipher Medicine, Chief Medical Officer (Photo: Business Wire) "We are thrilled to welcome Dr. Asgarian to our leadership team," said Alif Saleh, chief executive officer of Scipher Medicine. "His strong blend of experience as a health care clinician and business leader will serve us well as we pursue our critical mission." Dr. Asgarian joins Sci

      11/16/21 2:32:00 PM ET
      $CVS
      $EXAS
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
      Medical Specialities
      Health Care

    Exact Sciences Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      11/13/24 12:56:28 PM ET
      $EXAS
      Medical Specialities
      Health Care